In WT mice, α-PD-1 treatment showed limited efficacy, whereas in Myeloid-GAS6 KO mice, α-PD-1 treatment significantly enhanced antitumor immunity, as evidenced by reduced expression of immunosuppressive markers (CD163 and TIGIT) and increased expression of the cytotoxic marker perforin in the tumor microenvironment (Fig. 8A). Here, TIGIT is linked to neoplasm.